📰 Operations Items News
Operations Items News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Operations Items. Real-time updates on events, politics, business and more.
May 2, 2024
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1Presented preclinical data from LNCB74 at recent AACR annual meeting Cash of approximately $96.0 million...
March 12, 2024
12.03.2024 - IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient ...
March 14, 2023
14.03.2023 - Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025 Novel paralog-selective TEAD inhibitor, IK-930, advanced through multiple dose escalation cohorts, Fast Track and Orphan designations granted; ...
November 3, 2022
Discontinuing development of our NC318 programAdvancing clinical pipeline: NC410 combination, NC525, and NC762 Extending runway into mid-2025 (an...
March 8, 2022
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results License option agreement with Novartis for target-specific access... | March 8, 2022
March 3, 2022
03.03.2022 - Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of 2024 BELTSVILLE, Md., March 03, 2022 (GLOBE ...